Topics

Pharmaceutical Industry
MannKind agrees to license its inhaled-insulin drug Afrezza to Sanofi
MannKind agrees to license its inhaled-insulin drug Afrezza to Sanofi

Less than two months after receiving approval for an inhalable form of insulin, MannKind Corp. agreed to license the drug to Paris-based Sanofi in a deal that could provide the Valencia company with $925 million. Sanofi will initially pay MannKind $150 million to handle global commercial, regulatory and development activities for the drug, Afrezza, the companies announced Monday.  MannKind could also receive $775 million if Afrezza meets sales and development targets. The drug would be the only inhalable form of insulin on the market. In late June, the Food and Drug Administration approved the sale of Afrezza to treat people with Type 1 and Type 2 diabetes. Entrepreneur...

Loading